Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	POUR Luděk ŠVÁCHOVÁ Hana ADAM Zdeněk ALMÁŠI Martina BUREŠOVÁ Ivana BÜCHLER Tomáš KOVÁŘOVÁ Lucie NĚMEC Pavel PENKA Miroslav VORLÍČEK Jiří HÁJEK Roman
Year of publication	2010
Type	Article in Periodical
Magazine / Source	Annals of Hematology
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	multiple myeloma; angiogenesis; cytokines
Description	Angiogenesis plays a significant role in the pathogenesis of multiple myeloma (MM). We have measured concentrations of angiogenesis activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and hepatocyte growth factor (HGF), and inhibitors, including endostatin, thrombospondin-1 (TSP-1), and angiostatin in the peripheral and bone marrow blood of MM patients at diagnosis and after high-dose chemotherapy.
Related projects:	University Research Centre - Czech Myeloma Group From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies